论文部分内容阅读
目的观察来氟米特(LEF)、雷公藤多苷联合激素治疗IgA肾病的疗效和安全性。方法收集符合条件的60例中等量蛋白尿IgA肾病患者随机分为2组,试验组LEF联合中等量激素治疗,对照组雷公藤多苷联合中等量激素治疗,观察治疗前、后1、3、6个月的相关临床指标变化,并进行评价。结果试验组治疗后24h尿蛋白定量显著减少(P<0.01),血清白蛋白显著升高(P<0.01),完全缓解率为46.4%,总有效率为85.7%。与对照组比较疗效差异无统计学意义(P>0.05)。观察组起效快,不良反应轻微,患者耐受性好。结论来氟米特联合激素可以作为治疗IgA肾病的选择之一,且安全、有效。
Objective To observe the efficacy and safety of leflunomide (LEF) and tripterygium glycosides combined with hormones in the treatment of IgA nephropathy. Methods A total of 60 patients with moderate proteinuria IgA nephropathy were collected and randomly divided into two groups. The LEF combined with middle-dose hormone treatment and the control group tripterygium glycosides combined with middle-dose hormone treatment. 6 months of changes in relevant clinical indicators, and evaluation. Results The proteinuria of the experimental group was significantly decreased (P <0.01), serum albumin was significantly increased (P <0.01), the complete remission rate was 46.4% and the total effective rate was 85.7%. There was no significant difference in efficacy between the two groups (P> 0.05). The observation group developed fast, minor adverse reactions, patients with good tolerance. Conclusion Leflunomide combined with hormones can be used as one of the treatment options for IgA nephropathy, which is safe and effective.